These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33016647)

  • 1. Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker.
    Fischer GM; Carapeto FCL; Joon AY; Haydu LE; Chen H; Wang F; Van Arnam JS; McQuade JL; Wani K; Kirkwood JM; Thompson JF; Tetzlaff MT; Lazar AJ; Tawbi HA; Gershenwald JE; Scolyer RA; Long GV; Davies MA
    Cancer Med; 2020 Nov; 9(22):8650-8661. PubMed ID: 33016647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma.
    Franzke A; Probst-Kepper M; Buer J; Duensing S; Hoffmann R; Wittke F; Volkenandt M; Ganser A; Atzpodien J
    Br J Cancer; 1998 Jul; 78(1):40-5. PubMed ID: 9662248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a Circulating MicroRNA Profile as a Biomarker of Metastatic Cutaneous Melanoma.
    Armand-Labit V; Meyer N; Casanova A; Bonnabau H; Platzer V; Tournier E; Sansas B; Verdun S; Thouvenot B; Hilselberger B; Doncescu A; Lamant L; Lacroix-Triki M; Favre G; Pradines A
    Acta Derm Venereol; 2016 Jan; 96(1):29-34. PubMed ID: 26039581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma.
    Hamberg AP; Korse CM; Bonfrer JM; de Gast GC
    Melanoma Res; 2003 Feb; 13(1):45-9. PubMed ID: 12569284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumour DNA Reflects Tumour Burden Independently of Adverse Events Caused by Systemic Therapies for Melanoma.
    Ashida A; Sakaizawa K; Mikoshiba A; Kiniwa Y; Okuyama R
    Acta Derm Venereol; 2019 Nov; 99(12):1184-1185. PubMed ID: 31396634
    [No Abstract]   [Full Text] [Related]  

  • 6. Usefulness of serum 5-S-cysteinyl-dopa as a biomarker for predicting prognosis and detecting relapse in patients with advanced stage malignant melanoma.
    Umemura H; Yamasaki O; Kaji T; Otsuka M; Asagoe K; Takata M; Iwatsuki K
    J Dermatol; 2017 Apr; 44(4):449-454. PubMed ID: 27786364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum lactate dehydrogenase is a predictor of poor survival in malignant melanoma.
    Gao D; Ma X
    Panminerva Med; 2017 Dec; 59(4):332-337. PubMed ID: 27309261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum S100B levels correlate with stage, N status, mitotic rate and disease outcome in melanoma patients independent to LDH.
    Karonidis A; Mantzourani M; Gogas H; Tsoutsos D
    J BUON; 2017; 22(5):1296-1302. PubMed ID: 29135116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of neuron-specific enolase as a serum marker of metastatic melanoma.
    Sato S; Kato J; Sawada M; Horimoto K; Okura M; Hida T; Uhara H
    J Dermatol; 2020 Oct; 47(10):1141-1148. PubMed ID: 32734632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of serum lactate dehydrogenase level as a prognostic indicator in resected, high risk melanoma.
    Kumar AB; Aguilera JV; Velazquez A; Yan Y; Jakub J; Brewer J; Hieken T; Block M; McWilliams R; Otley C; Markovic S; Kottschade L
    Dermatol Ther; 2019 Mar; 32(2):e12813. PubMed ID: 30620137
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
    Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
    Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma.
    Hoejberg L; Bastholt L; Johansen JS; Christensen IJ; Gehl J; Schmidt H
    Melanoma Res; 2012 Aug; 22(4):287-93. PubMed ID: 22617301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic score for patients with advanced melanoma treated with ipilimumab.
    Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
    Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse.
    Egberts F; Hitschler WN; Weichenthal M; Hauschild A
    Melanoma Res; 2009 Feb; 19(1):31-5. PubMed ID: 19104452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma.
    Wang TS; Johnson TM; Cascade PN; Redman BG; Sondak VK; Schwartz JL
    J Am Acad Dermatol; 2004 Sep; 51(3):399-405. PubMed ID: 15337983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating biomarkers in malignant melanoma.
    Alegre E; Sammamed M; Fernández-Landázuri S; Zubiri L; González Á
    Adv Clin Chem; 2015; 69():47-89. PubMed ID: 25934359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.
    de Lecea MV; Palomares T; Al Kassam D; Cavia M; Geh JLC; de Llano P; Muñiz P; Armesto D; Martinez-Indart L; Alonso-Varona A
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):636-642. PubMed ID: 27633490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
    Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H
    Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor biomarkers in melanoma.
    Ugurel S; Utikal J; Becker JC
    Cancer Control; 2009 Jul; 16(3):219-24. PubMed ID: 19556961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
    Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
    Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.